XML 61 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Segments
 12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Segments Segments
The Company realigned its business in April 2019, and as a result, its CODM began regularly reviewing disaggregated financial information for various operating segments. The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) loss on impairment of goodwill and other noncurrent assets, (viii) equity in net loss of affiliates, and (ix) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. For the year ended December 31, 2020, the Company modified the current period definition of Segment Adjusted EBITDA to exclude adjustments recorded to reverse the difference of bonuses accrued as of December 31, 2019 compared to the value of equity awards granted, as the Company determined in March 2020 that those accrued bonuses would be paid through the grant of equity awards instead of cash. The Company also excluded noncash losses associated with settlement agreements. Segment Adjusted EBITDA for the years ended December 31, 2019 and 2018, were not impacted by these changes.
Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the businesses included in the Transactions and the operations of MBP Titan which are reported as discontinued operations (Note 3).
For the year ended December 31, 2020, the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) Trans Ova, and (iv) the Human Biotherapeutics division. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December 31, 2020. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. The Company's Human Biotherapeutics division is an operating division within Precigen which in 2020 and 2019 included the Company's majority-owned subsidiary, Triple-Gene LLC, and its collaborations with Castle Creek (Note 6). The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to be reported separately.
Information by reportable segment was as follows:
PGEN TherapeuticsActoBioTrans OvaHuman BiotherapeuticsAll OtherTotal
Goodwill
Balances at December 31, 2018$15,232 $1,788 $46,236 $— $20,736 $83,992 
Reallocations from changes to reporting units— — — 482 (482)— 
Impairments— — (29,642)— (178)(29,820)
Foreign currency translation adjustments— (53)— — — (53)
Balances at December 31, 201915,232 1,735 16,594 482 20,076 54,119 
Foreign currency translation adjustments— 244 — — — 244 
Balances at December 31, 2020$15,232 $1,979 $16,594 $482 $20,076 $54,363 

Year Ended December 31, 2020
PGEN TherapeuticsActoBioTrans OvaHuman BiotherapeuticsAll OtherTotal
Revenues from external customers$776 $3,053 $71,186 $17,810 $10,299 $103,124 
Intersegment revenues5,006 (3)340 — 281 5,624 
Total segment revenues$5,782 $3,050 $71,526 $17,810 $10,580 $108,748 
Segment Adjusted EBITDA$(25,611)$(7,861)$2,624 $(2,139)$4,274 $(28,713)

Year Ended December 31, 2019
PGEN TherapeuticsActoBioTrans OvaHuman BiotherapeuticsAll OtherTotal
Revenues from external customers$2,227 $(364)$68,672 $3,713 $12,514 $86,762 
Intersegment revenues11,341 498 1,361 — 1,270 14,470 
Total segment revenues$13,568 $134 $70,033 $3,713 $13,784 $101,232 
Segment Adjusted EBITDA$(30,164)$(13,662)$(6,337)$(1,051)$(4,901)$(56,115)

Year Ended December 31, 2018
PGEN TherapeuticsActoBioTrans OvaHuman BiotherapeuticsAll OtherTotal
Revenues from external customers$29,021 $6,684 $75,178 $— $30,213 $141,096 
Intersegment revenues617 840 558 — 255 2,270 
Total segment revenues$29,638 $7,524 $75,736 $— $30,468 $143,366 
Segment Adjusted EBITDA$(32,832)$(12,797)$(5,730)$— $(10,708)$(62,067)
The table below reconciles total segment revenues from reportable segments to total consolidated revenues:
Year Ended December 31,
202020192018
Total segment revenues from reportable segments$98,168 $87,448 $112,898 
Other revenues, including from other operating segments10,634 17,964 40,841 
Elimination of intersegment revenues(5,624)(14,690)(2,561)
Total consolidated revenues$103,178 $90,722 $151,178 
The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:
Year Ended December 31,
202020192018
Segment Adjusted EBITDA for reportable segments$(32,987)$(51,214)$(51,359)
All Other Segment Adjusted EBITDA4,274 (4,901)(10,708)
Remove cash paid for capital expenditures and investments in affiliates6,970 12,512 15,276 
Add recognition of previously deferred revenue associated with upfront and milestone payments25,005 14,721 33,204 
Other expenses:
Interest expense(18,400)(17,666)(8,473)
Depreciation and amortization(15,042)(16,142)(20,612)
Impairment losses(920)(30,810)— 
Reacquisition of in-process research and development— — (236,748)
Loss on settlement agreement(11,436)— — 
Stock-based compensation expense(19,746)(15,098)(30,554)
Adjustment related to accrued bonuses paid in equity awards2,833 — — 
Equity in net loss of affiliates(1,138)(2,416)(8,986)
Other11 67 — 
Unallocated corporate costs(37,566)(46,011)(74,609)
Eliminations(5,713)(14,306)(2,343)
Consolidated net loss from continuing operations before income taxes$(103,855)$(171,264)$(395,912)
As of December 31, 2020 and 2019, the Company had $5,908 and $6,724, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $595, $1,401, and $6,255 for the years ended December 31, 2020, 2019 and 2018, respectively.